Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
D11454 Repotrectinib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D11454 Repotrectinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
INSR family
ROS1* [HSA_VAR:6098v1]
D11454 Repotrectinib (JAN/USAN) <US>
TRK family
NTRK1 (TRKA)
D11454 Repotrectinib (JAN/USAN) <US>
NTRK2 (TRKB)
D11454 Repotrectinib (JAN/USAN) <US>
NTRK3 (TRKC)
D11454 Repotrectinib (JAN/USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11454
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11454
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11454
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D11454